Nurix Therapeutics (NRIX) Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025 summary

Oncology program updates

• NX-5948 is advancing toward pivotal trials, with a single-arm study of 100+ patients planned for 2025 and a randomized confirmatory trial to follow closely.

• Accelerated approval pathway is anticipated based on current results, with trial initiation expected this year.

• Duration of response is not yet calculable as patients remain on study, but expectations are for superior durability compared to non-covalent inhibitors.

• Safety profile appears favorable due to the degrader mechanism requiring much lower drug levels, reducing off-target effects.

• Enrollment is ahead of schedule, with key data updates expected at EHA and ASH conferences this year.

Competitive landscape and strategy

• Focused, nimble approach and decade-long expertise in degrader molecules are seen as advantages over larger competitors.

• The strategy is to position degraders as superior to both covalent and non-covalent BTK inhibitors, aiming to displace or replace them.

• Activity in kinase-null mutations and wild-type BTK patients suggests potential in later-line and broader indications.

• Earlier line settings are not yet reflected in share price, indicating potential upside.

Immunology and inflammation (I&I) pipeline

• Stepwise approach in I&I starts with autoimmune hemolytic anemia, leveraging rapid and objective clinical readouts.

• Cohorts are open in CLL with autoimmune hemolytic anemia, with plans to expand into non-oncology and dermatology indications.

• Multiple sclerosis is a key target due to demonstrated brain penetrance and efficacy in CNS lymphoma.

• The degrader mechanism is expected to offer improved efficacy and safety by removing both kinase and scaffolding functions of BTK.

• More details on autoimmune strategy are expected later this year as programs progress.